BlackRock, Inc. 13D and 13G filings for Akebia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
15,141,768 6.100% |
-55,439 (-0.36%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
15,197,207 7.200% |
0 (Unchanged) |
Filing |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
15,197,207 7.200% |
10,857,181 (+250.16%) |
Filing |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
4,340,026 2.400% |
-9,784,189 (-69.27%) |
Filing |
| 2022-02-07 4:41 pm Purchase |
2021-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
14,124,215 8.100% |
2,726,667 (+23.92%) |
Filing |
| 2021-01-28 5:56 pm Purchase |
2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
BLACKROCK INC BLK |
11,397,548 7.900% |
1,136,401 (+11.07%) |
Filing |